You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVerapamil
Accession NumberDB00661  (APRD00335)
TypeSmall Molecule
GroupsApproved
Description

A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]

Structure
Thumb
Synonyms
Calan
Calan sr
Covera-hs
CP-16533-1
CP-165331
D-365
Iproveratril
Isoptin
Isoptin sr
Tarka
Vérapamil
Verapamil
Verapamilo
Verapamilum
Verelan
External Identifiers
  • CP 16533-1
  • D 365
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-verapamil - 120mgtablet120 mgoralAltimed Pharma Inc.1990-12-312004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Alti-verapamil - 80mgtablet80 mgoralAltimed Pharma Inc.1990-12-312004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Calantablet, film coated80 mg/1oralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calantablet, film coated120 mg/1oralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calan SRtablet, film coated, extended release180 mg/1oralG.D. Searle LLC Division of Pfizer Inc1989-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calan SRtablet, film coated, extended release120 mg/1oralG.D. Searle LLC Division of Pfizer Inc1991-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calan SRtablet, film coated, extended release240 mg/1oralG.D. Searle LLC Division of Pfizer Inc1986-12-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Covera-HStablet, extended release240 mg/1oralG.D. Searle LLC Division of Pfizer Inc1996-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Covera-HStablet, extended release180 mg/1oralG.D. Searle LLC Division of Pfizer Inc1996-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Covera-HStablet (extended-release)240 mgoralPfizer Canada Inc1997-11-132013-02-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Covera-HStablet (extended-release)180 mgoralPfizer Canada Inc1997-11-132013-02-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-verapamil SR 240mg Tabletstablet (extended-release)240 mgoralDominion Pharmacal1999-12-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin Inj 2.5mg/mlliquid2.5 mgintravenousAbbott Laboratories, Limited1984-12-312007-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin SRtablet (extended-release)240 mgoralBgp Pharma Ulc1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin SRtablet (extended-release)180 mgoralBgp Pharma Ulc1994-04-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin SRtablet (extended-release)120 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin Tab 120mgtablet120 mgoralAbbott Laboratories, Limited1982-12-312007-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Isoptin Tab 80mgtablet80 mgoralAbbott Laboratories, Limited1982-12-312007-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Verapamil Tabletstablet120 mgoralMedican Pharma Incorporated1999-03-082011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Med Verapamil Tabletstablet80 mgoralMedican Pharma Incorporated1999-03-082011-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-verapamiltablet120 mgoralMylan Pharmaceuticals Ulc1998-05-11Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-verapamiltablet80 mgoralMylan Pharmaceuticals Ulc1998-05-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-verapamil SRtablet (extended-release)240 mgoralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-verapamil SRtablet (extended-release)120 mgoralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-verapamil SRtablet (extended-release)180 mgoralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-veramiltablet120 mgoralTeva Canada Limited1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-veramiltablet80 mgoralTeva Canada Limited1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-veramil SRtablet (extended-release)240 mgoralTeva Canada Limited1996-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-verap SRtablet (extended-release)240 mgoralNu Pharm Inc2004-07-192012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-verap SRtablet (extended-release)180 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-verap SRtablet (extended-release)120 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-verap Tab 120mgtablet120 mgoralNu Pharm Inc1990-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-verap Tab 80mgtablet80 mgoralNu Pharm Inc1990-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-verapamil - 120mgtablet120 mgoralPentapharm Ltd.1997-06-252004-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-verapamil - 80mgtablet80 mgoralPentapharm Ltd.1997-06-252004-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-verapamil SRtablet (extended-release)240 mgoralPharmel Inc2002-05-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-verapamil SRtablet (extended-release)240 mgoralPharmascience Inc1999-09-01Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-verapamil SRtablet (extended-release)180 mgoralPro Doc Limitee2009-06-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-verapamil SRtablet (extended-release)120 mgoralPro Doc Limitee2009-06-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-verapamil SRtablet (extended-release)240 mgoralPro Doc Limitee2008-07-09Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Riva-verapamil SRtablet (extended-release)240 mgoralLaboratoire Riva Inc2005-09-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-verapamil Tab 120mgtablet120 mgoralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-verapamil Tab 80mgtablet80 mgoralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralbryant ranch prepack1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release200 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets120 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release100 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralPhysicians Total Care, Inc.2009-02-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets180 mg/1oralCarilion Materials Management1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets240 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets120 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release300 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, delayed release pellets180 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloride Injection 2.5mg/mlsolution2.5 mgintravenousHospira Healthcare Corporation1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil Hydrochloride Injection USPliquid2.5 mgintravenousSandoz Canada Incorporated1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil Injection 2.5mg/mlliquid2.5 mgintravenousNovopharm Limited1994-12-312005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil SRtablet (extended-release)240 mgoralSorres Pharma Inc2009-06-222014-06-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil Tab 80mgtablet80 mgoralPro Doc Limitee1990-12-312012-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamil-120 Tabtablet120 mgoralPro Doc Limitee1990-12-312009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verelancapsule, delayed release pellets180 mg/1oralUCB, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets240 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets180 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule (sustained-release)120 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verelancapsule, delayed release pellets120 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule (sustained-release)180 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verelancapsule, delayed release pellets360 mg/1oralPhysicians Total Care, Inc.2003-06-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule (sustained-release)240 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verelancapsule, delayed release pellets240 mg/1oralPhysicians Total Care, Inc.2004-08-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets360 mg/1oralUCB, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets240 mg/1oralUCB, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets120 mg/1oralUCB, Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelancapsule, delayed release pellets360 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release300 mg/1oralUCB, Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release200 mg/1oralUCB, Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release100 mg/1oralUCB, Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release300 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release200 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release100 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verelan PMcapsule, extended release300 mg/1oralbryant ranch prepack1998-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-verap SRtablet (extended-release)240 mgoralApotex Inc2003-04-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-verap SRtablet (extended-release)180 mgoralApotex Inc2003-04-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-verap SRtablet (extended-release)120 mgoralApotex Inc2003-04-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-verap Tab 80mgtablet80 mgoralApotex Inc1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-verap Tablet 120mgtablet120 mgoralApotex Inc1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Verapamiltablet, film coated, extended release120 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release180 mg/1oralSt Marys Medical Park Pharmacy2013-02-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, extended release180 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release180 mg/1oralUnit Dose Services2012-11-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release240 mg/1oralApotex Corp.2012-11-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release240 mg/1oralAmerican Health Packaging2014-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release180 mg/1oralAmerican Health Packaging2014-01-142015-12-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release180 mg/1oralApotex Corp.2012-11-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release120 mg/1oralAmerican Health Packaging2014-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamiltablet, film coated, extended release120 mg/1oralApotex Corp.2012-11-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPhysicians Total Care, Inc.2000-05-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralTeva Pharmaceuticals USA Inc2014-03-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release240 mg/1oralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralbryant ranch prepack1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release120 mg/1oralMylan Institutional Inc.1999-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release240 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralActavis Pharma, Inc.1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release180 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralBlenheim Pharmacal, Inc.2010-08-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralCardinal Health2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralMylan Pharmaceuticals Inc.1997-09-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet40 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralA S Medication Solutions Llc1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1987-05-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralMylan Institutional Inc.1996-04-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralBlenheim Pharmacal, Inc.2011-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet120 mg/1oralREMEDYREPACK INC.2014-06-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralCardinal Health1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralMylan Pharmaceuticals Inc.1997-02-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release240 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release180 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release240 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralUnit Dose Services2011-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet120 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralClinical Solutions Wholesale1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release200 mg/1oralPhysicians Total Care, Inc.2010-05-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralMylan Pharmaceuticals Inc.1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-08-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralMajor Pharmaceuticals1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release180 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet80 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated40 mg/1oralClinical Solutions Wholesale1993-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release300 mg/1oralPhysicians Total Care, Inc.2007-12-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralMylan Pharmaceuticals Inc.2012-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release180 mg/1oralREMEDYREPACK INC.2011-07-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralMajor Pharmaceuticals1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated40 mg/1oralCarilion Materials Management1993-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release120 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralUnit Dose Services2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralRebel Distributors Corp2010-04-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralClinical Solutions Wholesale2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralMylan Pharmaceuticals Inc.2012-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release120 mg/1oralREMEDYREPACK INC.2010-11-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet240 mg/1oralREMEDYREPACK INC.2012-10-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet120 mg/1oralA S Medication Solutions Llc2011-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet120 mg/1oralRebel Distributors Corp1996-02-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralPhysicians Total Care, Inc.1996-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralTeva Pharmaceuticals USA Inc2014-04-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralAphena Pharma Solutions Tennessee, Llc1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralClinical Solutions Wholesale1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralCardinal Health2012-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet80 mg/1oralRebel Distributors Corp1995-04-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPreferred Pharmaceuticals, Inc.2012-06-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralMylan Institutional Inc.1998-11-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release180 mg/1oralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralActavis Pharma, Inc.1986-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralPhysicians Total Care, Inc.1996-02-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralbryant ranch prepack2010-04-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release180 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1998-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridecapsule, extended release100 mg/1oralPhysicians Total Care, Inc.2008-08-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralTeva Pharmaceuticals USA Inc2014-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralbryant ranch prepack1997-10-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release240 mg/301oralNorthwind Pharmaceuticals2014-05-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralClinical Solutions Wholesale2011-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated40 mg/1oralActavis Pharma, Inc.1993-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-11-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated120 mg/1oralBlenheim Pharmacal, Inc.2013-12-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release240 mg/1oralPreferred Pharmaceuticals, Inc.2013-09-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralMylan Institutional Inc.1998-04-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet120 mg/1oralREMEDYREPACK INC.2011-12-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated80 mg/1oralPhysicians Total Care, Inc.1995-04-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralbryant ranch prepack1992-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloridetablet, extended release120 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1987-05-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloride PMcapsule, extended release300 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloride PMcapsule, extended release200 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Verapamil Hydrochloride PMcapsule, extended release100 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
BosoptinBosnalijek
IsoptinAbbott
VerisopGerard
VerminRatiopharm
VerminePharmasant
VerogalidIvax
Verogalid ERIvax
VerpamilMylan
VertabTrinity-Chiesi
VetrimilCCPC
ZolveraRosemont
Brand mixtures
NameLabellerIngredients
TarkaAbb Vie Inc.
Trandolapril and Verapamil HydrochlorideGlenmark Pharmaceuticals Inc., Usa
Trandolapril and Verapamil Hydrochloride ERGreenstone LLC
Salts
Name/CASStructureProperties
Verapamil Hydrochloride
152-11-4
Thumb
  • InChI Key: DOQPXTMNIUCOSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 490.259835453
  • Average Mass: 491.063
DBSALT000534
Categories
CAS number52-53-9
WeightAverage: 454.6016
Monoisotopic: 454.283157714
Chemical FormulaC27H38N2O4
InChI KeyInChIKey=SGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Phenylpropane
  • Phenethylamine
  • Benzyl-cyanide
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Tertiary aliphatic amine
  • Tertiary amine
  • Nitrile
  • Carbonitrile
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, angina, and cluster headache prophylaxis.
PharmacodynamicsVerapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Mechanism of actionVerapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.
Absorption90%
Volume of distributionNot Available
Protein binding90%
Metabolism
SubstrateEnzymesProduct
Verapamil
O-Desmethylverapamil (D-702)Details
Verapamil
Verapamil metabolite D-617Details
Verapamil
NorverapamilDetails
Verapamil
O-Desmethylverapamil (D-703)Details
O-Desmethylverapamil (D-702)
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Not Available
Verapamil metabolite PR-25Details
Norverapamil
Verapamil metabolite D-715 (PR-22)Details
Norverapamil
Verapamil metabolite D-620Details
Route of eliminationApproximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
Half life2.8-7.4 hours
ClearanceNot Available
ToxicityLD50=8 mg/kg (i.v. in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9371
Blood Brain Barrier+0.6323
Caco-2 permeable+0.738
P-glycoprotein substrateSubstrate0.7874
P-glycoprotein inhibitor IInhibitor0.9056
P-glycoprotein inhibitor IIInhibitor0.855
Renal organic cation transporterInhibitor0.6259
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8706
CYP450 3A4 substrateSubstrate0.7657
CYP450 1A2 substrateNon-inhibitor0.9553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9181
Ames testNon AMES toxic0.8393
CarcinogenicityNon-carcinogens0.6463
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4137 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7687
hERG inhibition (predictor II)Inhibitor0.8188
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mylan pharmaceuticals inc
  • Elan drug delivery inc
  • Gd searle llc
  • Fsc laboratories inc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Ranbaxy laboratories inc
  • Glenmark generics ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Pliva inc
  • Actavis elizabeth llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral80 mg
Tablet, film coatedoral120 mg/1
Tablet, film coatedoral80 mg/1
Tablet, film coated, extended releaseoral120 mg/1
Tablet, film coated, extended releaseoral180 mg/1
Tablet, film coated, extended releaseoral240 mg/1
Tablet, extended releaseoral180 mg/1
Tablet, extended releaseoral240 mg/1
Tabletoral120 mg
Tablet (extended-release)oral120 mg
Tablet (extended-release)oral180 mg
Tablet (extended-release)oral240 mg
Tablet (extended-release)oral
Tablet, film coated, extended releaseoral
Capsule, extended releaseoral120 mg/1
Capsule, extended releaseoral180 mg/1
Capsule, extended releaseoral240 mg/1
Injection, solutionintravenous2.5 mg/mL
Tabletoral120 mg/1
Tabletoral240 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tablet, extended releaseoral120 mg/1
Tablet, extended releaseoral240 mg/301
Tablet, film coatedoral40 mg/1
Solutionintravenous2.5 mg
Liquidintravenous2.5 mg
Capsule (sustained-release)oral120 mg
Capsule (sustained-release)oral180 mg
Capsule (sustained-release)oral240 mg
Capsule, delayed release pelletsoral120 mg/1
Capsule, delayed release pelletsoral180 mg/1
Capsule, delayed release pelletsoral240 mg/1
Capsule, delayed release pelletsoral360 mg/1
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Prices
Unit descriptionCostUnit
Verelan 360 mg 24 Hour Capsule6.82USD capsule
Verelan 360 mg cap pellet6.73USD pellet
Verelan pm 300 mg cap pellet5.87USD pellet
Verelan 240 mg 24 Hour Capsule4.76USD capsule
Verelan 240 mg cap pellet4.58USD pellet
Verelan 180 mg 24 Hour Capsule4.22USD capsule
Verelan 180 mg cap pellet4.06USD pellet
Verelan pm 200 mg cap pellet4.04USD pellet
Verelan 120 mg cap pellet3.87USD pellet
Verapamil HCl CR 300 mg 24 Hour Capsule3.82USD capsule
Isoptin sr 240 mg tablet3.32USD tablet
Verapamil hcl powder3.24USD g
Calan SR 240 mg Controlled Release Tabs3.15USD tab
Isoptin SR 240 mg Controlled Release Tabs3.14USD tab
Verelan pm 100 mg cap pellet3.13USD pellet
Calan sr 240 mg caplet3.09USD caplet
Covera-HS 240 mg 24 Hour tablet3.09USD tablet
Covera-hs 240 mg tablet sa2.97USD tablet
Isoptin sr 180 mg tablet2.9USD tablet
Calan SR 180 mg Controlled Release Tabs2.8USD tab
Isoptin SR 180 mg Controlled Release Tabs2.74USD tab
Calan sr 180 mg caplet2.7USD caplet
Verapamil HCl CR 200 mg 24 Hour Capsule2.62USD capsule
Isoptin sr 120 mg tablet2.29USD tablet
Calan SR 120 mg Controlled Release Tabs2.27USD tab
Covera-HS 180 mg 24 Hour tablet2.2USD tablet
Isoptin SR 120 mg Controlled Release Tabs2.16USD tab
Calan sr 120 mg caplet2.13USD caplet
Covera-hs 180 mg tablet sa2.11USD tablet
Verapamil HCl CR 360 mg 24 Hour Capsule2.1USD capsule
Verapamil HCl CR 100 mg 24 Hour Capsule2.04USD capsule
Isoptin Sr 240 mg Sustained-Release Tablet2.03USD tablet
Calan sr 240 mg caplet sa1.77USD caplet
Verapamil HCl CR 240 mg 24 Hour Capsule1.69USD capsule
Verapamil HCl CR 240 mg Controlled Release Tabs1.6USD tab
Calan 120 mg tablet1.56USD tablet
Isoptin Sr 180 mg Sustained-Release Tablet1.52USD tablet
Verapamil HCl CR 180 mg 24 Hour Capsule1.5USD capsule
Calan sr 180 mg caplet sa1.46USD caplet
Verapamil HCl CR 120 mg 24 Hour Capsule1.43USD capsule
Verapamil HCl CR 180 mg Controlled Release Tabs1.41USD tab
Isoptin Sr 120 mg Sustained-Release Tablet1.34USD tablet
Calan 80 mg tablet1.25USD tablet
Verapamil 2.5 mg/ml vial1.18USD ml
Verapamil HCl CR 120 mg Controlled Release Tabs1.12USD tab
Apo-Verap Sr 240 mg Sustained-Release Tablet0.91USD tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Calan 40 mg tablet0.76USD tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet0.72USD tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet0.72USD tablet
Verapamil HCl 120 mg tablet0.71USD tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet0.69USD tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet0.69USD tablet
Verapamil HCl 80 mg tablet0.56USD tablet
Apo-Verap 120 mg Tablet0.45USD tablet
Mylan-Verapamil 120 mg Tablet0.45USD tablet
Nu-Verap 120 mg Tablet0.45USD tablet
Verapamil 120 mg tablet0.39USD tablet
Verapamil 80 mg tablet0.31USD tablet
Verapamil HCl 40 mg tablet0.29USD tablet
Apo-Verap 80 mg Tablet0.29USD tablet
Mylan-Verapamil 80 mg Tablet0.29USD tablet
Nu-Verap 80 mg Tablet0.29USD tablet
Verapamil 40 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States57859941992-10-222009-10-22
United States60963391997-04-042017-04-04
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point243-246 °C at 1.00E-02 mm HgPhysProp
water solubility4.47 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
Caco2 permeability-4.58ADME Research, USCD
pKa8.92SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0u08z00000-6a46ea2d5eed6d8b01ebView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-g70zx00000-80d342090a0be3344e82View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0zmgi00000-2def387c7c93ab211423View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-0000z00000-4cde9a4b3a4f83d16afcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-0000z00000-980b47834e505d54a0e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-0z18x00000-ae024239c46b33917426View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-0z24000000-81d1159b3102cff76218View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-1z20000000-d9c344fee7b45b4030e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0z5g000000-070bdb975910e9aae99cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0cz0000000-f41d80462c5d06c4f001View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-8zv0000000-9a2ab0bcab33f7eaac6bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0z01000000-252a9989a8511cb2db80View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0z00000000-4fd6ca2c6c19c3bbf8f0View in MoNA
MSMass Spectrum (Electron Ionization)splash10-ek5z000000-b5e0b9e0caac5cb57222View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, “Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms.” U.S. Patent US4859469, issued April, 1987.

US4859469
General References
  1. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. Pubmed
External Links
ATC CodesC08DA01
AHFS Codes
  • 24:28.92
PDB EntriesNot Available
FDA labelDownload (1.9 MB)
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Verapamil can be increased when it is combined with Abiraterone.
AcetaminophenThe metabolism of Verapamil can be increased when combined with Acetaminophen.
Acetylsalicylic acidVerapamil may increase the anticoagulant activities of Acetylsalicylic acid.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Verapamil.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Verapamil.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.
AmifostineVerapamil may increase the hypotensive activities of Amifostine.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Verapamil.
AmlodipineAmlodipine may increase the hypotensive activities of Verapamil.
AmobarbitalThe metabolism of Verapamil can be increased when combined with Amobarbital.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Verapamil.
AprepitantThe serum concentration of Verapamil can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.
AtorvastatinThe serum concentration of Verapamil can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Verapamil is combined with Atosiban.
Atracurium besylateVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Verapamil.
AzithromycinThe serum concentration of Verapamil can be increased when it is combined with Azithromycin.
BatimastatThe metabolism of Verapamil can be decreased when combined with Batimastat.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Verapamil.
BexaroteneThe serum concentration of Verapamil can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Verapamil can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.
BretyliumBretylium may increase the bradycardic activities of Verapamil.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.
BrimonidineBrimonidine may increase the antihypertensive activities of Verapamil.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Verapamil.
BuspironeThe metabolism of Buspirone can be decreased when combined with Verapamil.
ButabarbitalThe metabolism of Verapamil can be increased when combined with Butabarbital.
ButalbitalThe metabolism of Verapamil can be increased when combined with Butalbital.
ButethalThe metabolism of Verapamil can be increased when combined with Butethal.
CaffeineThe metabolism of Verapamil can be increased when combined with Caffeine.
Calcium AcetateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.
Calcium carbonateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium carbonate.
Calcium ChlorideThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.
Calcium citrateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium citrate.
Calcium gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Verapamil.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Verapamil.
CeritinibVerapamil may increase the bradycardic activities of Ceritinib.
CetirizineThe serum concentration of Cetirizine can be increased when it is combined with Verapamil.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Verapamil.
CimetidineThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Verapamil.
Cisatracurium besylateVerapamil may increase the neuromuscular blocking activities of Cisatracurium besylate.
ClarithromycinThe serum concentration of Verapamil can be increased when it is combined with Clarithromycin.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.
CobicistatThe serum concentration of Verapamil can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Verapamil.
ConivaptanThe serum concentration of Verapamil can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Verapamil.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Verapamil.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Verapamil.
DabrafenibThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Verapamil can be increased when it is combined with Daclatasvir.
DantroleneDantrolene may increase the hyperkalemic activities of Verapamil.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.
DarunavirThe serum concentration of Verapamil can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Verapamil.
DeferasiroxThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.
DesloratadineThe serum concentration of Desloratadine can be increased when it is combined with Verapamil.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Verapamil.
DiazoxideDiazoxide may increase the hypotensive activities of Verapamil.
DigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Digoxin.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Verapamil.
DipyridamoleThe serum concentration of Verapamil can be increased when it is combined with Dipyridamole.
DisopyramideThe risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Verapamil.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Verapamil.
DoxazosinDoxazosin may increase the hypotensive activities of Verapamil.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Verapamil.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Verapamil.
DronedaroneVerapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Verapamil.
DuloxetineVerapamil may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.
EfavirenzThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Verapamil.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Verapamil.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Verapamil.
ErythromycinThe serum concentration of Verapamil can be increased when it is combined with Erythromycin.
EsmololEsmolol may increase the bradycardic activities of Verapamil.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Verapamil.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Verapamil.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Verapamil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Verapamil.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.
FexofenadineThe bioavailability of Fexofenadine can be increased when combined with Verapamil.
FingolimodVerapamil may increase the bradycardic activities of Fingolimod.
FlecainideThe risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Verapamil.
FluconazoleThe serum concentration of Verapamil can be increased when it is combined with Fluconazole.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Verapamil.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Verapamil.
FosaprepitantThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.
Fusidic AcidThe serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Verapamil.
HeptabarbitalThe metabolism of Verapamil can be increased when combined with Heptabarbital.
HexobarbitalThe metabolism of Verapamil can be increased when combined with Hexobarbital.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Verapamil.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Verapamil.
IdelalisibThe serum concentration of Verapamil can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Verapamil.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Verapamil.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Verapamil.
IsoflurophateThe metabolism of Verapamil can be decreased when combined with Isoflurophate.
ItraconazoleThe serum concentration of Verapamil can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Verapamil.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Verapamil.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Verapamil.
KetoconazoleThe serum concentration of Verapamil can be increased when it is combined with Ketoconazole.
LacosamideVerapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Verapamil.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Verapamil.
LevodopaVerapamil may increase the orthostatic hypotensive activities of Levodopa.
LithiumVerapamil may increase the neurotoxic activities of Lithium.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Verapamil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Verapamil.
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Verapamil.
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Verapamil.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Verapamil.
LuliconazoleThe serum concentration of Verapamil can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.
Magnesium chlorideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium chloride.
Magnesium citrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium citrate.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.
MefloquineThe serum concentration of Verapamil can be increased when it is combined with Mefloquine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.
MethohexitalThe metabolism of Verapamil can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Verapamil.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Verapamil.
MidodrineVerapamil may increase the bradycardic activities of Midodrine.
MifepristoneThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.
MirabegronThe serum concentration of Verapamil can be increased when it is combined with Mirabegron.
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Verapamil.
MitotaneThe serum concentration of Verapamil can be decreased when it is combined with Mitotane.
MolsidomineMolsidomine may increase the hypotensive activities of Verapamil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Verapamil.
MoxonidineMoxonidine may increase the hypotensive activities of Verapamil.
NadololVerapamil may increase the hypotensive activities of Nadolol.
NafcillinThe metabolism of Verapamil can be increased when combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Verapamil.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Verapamil.
NetupitantThe serum concentration of Verapamil can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Verapamil.
NicorandilNicorandil may increase the hypotensive activities of Verapamil.
NilotinibThe serum concentration of Verapamil can be increased when it is combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Verapamil.
NitroprussideVerapamil may increase the hypotensive activities of Nitroprusside.
NorgestimateThe serum concentration of Norgestimate can be increased when it is combined with Verapamil.
ObinutuzumabVerapamil may increase the hypotensive activities of Obinutuzumab.
OctreotideOctreotide may increase the bradycardic activities of Verapamil.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Verapamil.
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Verapamil.
OxycodoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Verapamil.
PalbociclibThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Verapamil.
PancuroniumVerapamil may increase the neuromuscular blocking activities of Pancuronium.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.
PentobarbitalThe metabolism of Verapamil can be increased when combined with Pentobarbital.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Verapamil.
PhenelzinePhenelzine may increase the hypotensive activities of Verapamil.
PhenobarbitalThe metabolism of Verapamil can be increased when combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Verapamil.
PhentolaminePhentolamine may increase the hypotensive activities of Verapamil.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Verapamil.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Verapamil.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Verapamil.
PrazosinPrazosin may increase the hypotensive activities of Verapamil.
PrimidoneThe metabolism of Verapamil can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Verapamil can be increased when it is combined with Progesterone.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Verapamil.
PropranololThe serum concentration of Verapamil can be increased when it is combined with Propranolol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Verapamil.
QuinidineQuinidine may increase the hypotensive activities of Verapamil.
QuinineThe serum concentration of Quinine can be increased when it is combined with Verapamil.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Verapamil.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Verapamil.
RegorafenibRegorafenib may increase the bradycardic activities of Verapamil.
ReserpineThe serum concentration of Verapamil can be increased when it is combined with Reserpine.
RifabutinThe serum concentration of Verapamil can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Verapamil can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Verapamil can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Verapamil.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Verapamil.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Verapamil.
RituximabVerapamil may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Verapamil.
RocuroniumVerapamil may increase the neuromuscular blocking activities of Rocuronium.
RolapitantThe serum concentration of Verapamil can be increased when it is combined with Rolapitant.
RuxolitinibRuxolitinib may increase the bradycardic activities of Verapamil.
Salicylate-sodiumVerapamil may increase the anticoagulant activities of Salicylate-sodium.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.
SaquinavirThe serum concentration of Verapamil can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Verapamil.
SecobarbitalThe metabolism of Verapamil can be increased when combined with Secobarbital.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Verapamil.
SiltuximabThe serum concentration of Verapamil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Verapamil.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Verapamil.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Verapamil.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Verapamil.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Verapamil.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Verapamil.
St. John's WortThe serum concentration of Verapamil can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Verapamil can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Verapamil.
SulfisoxazoleThe serum concentration of Verapamil can be increased when it is combined with Sulfisoxazole.
SunitinibThe serum concentration of Verapamil can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Verapamil.
TadalafilTadalafil may increase the antihypertensive activities of Verapamil.
TamoxifenThe serum concentration of Verapamil can be increased when it is combined with Tamoxifen.
TamsulosinTamsulosin may increase the hypotensive activities of Verapamil.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Verapamil.
TelithromycinTelithromycin may increase the bradycardic activities of Verapamil.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Verapamil.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Verapamil.
TerazosinTerazosin may increase the hypotensive activities of Verapamil.
TesmilifeneThe serum concentration of Verapamil can be decreased when it is combined with Tesmilifene.
TipranavirThe serum concentration of Verapamil can be decreased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Verapamil.
TocilizumabThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Verapamil.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Verapamil.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Verapamil.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Verapamil.
TranylcypromineTranylcypromine may increase the hypotensive activities of Verapamil.
TreprostinilTreprostinil may increase the hypotensive activities of Verapamil.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Verapamil.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.
VandetanibThe serum concentration of Verapamil can be increased when it is combined with Vandetanib.
VardenafilVardenafil may increase the antihypertensive activities of Verapamil.
VecuroniumVerapamil may increase the neuromuscular blocking activities of Vecuronium.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Verapamil.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Verapamil.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Verapamil.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Verapamil.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Verapamil.
YohimbineYohimbine may decrease the antihypertensive activities of Verapamil.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Verapamil.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid natural licorice.
  • Avoid taking with grapefruit juice.
  • Take with food.

Targets

1. Voltage-dependent L-type calcium channel subunit alpha-1C

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1C Q13936 Details

References:

  1. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. Pubmed
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. Pubmed
  3. Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. Pubmed
  4. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

2. Voltage-dependent L-type calcium channel subunit alpha-1D

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1D Q01668 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

3. Voltage-dependent L-type calcium channel subunit alpha-1F

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1F O60840 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

4. Voltage-dependent L-type calcium channel subunit alpha-1S

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit alpha-1S Q13698 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

5. Voltage-dependent L-type calcium channel subunit beta-1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-1 Q02641 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

6. Voltage-dependent L-type calcium channel subunit beta-2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-2 Q08289 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

7. Voltage-dependent L-type calcium channel subunit beta-3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-3 P54284 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

8. Voltage-dependent L-type calcium channel subunit beta-4

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent L-type calcium channel subunit beta-4 O00305 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

9. Voltage-dependent T-type calcium channel subunit alpha-1I

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent T-type calcium channel subunit alpha-1I Q9P0X4 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

10. Voltage-dependent T-type calcium channel subunit alpha-1G

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent T-type calcium channel subunit alpha-1G O43497 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  3. Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. Pubmed

11. Voltage-dependent N-type calcium channel subunit alpha-1B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent N-type calcium channel subunit alpha-1B Q00975 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

12. Voltage-dependent P/Q-type calcium channel subunit alpha-1A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Voltage-dependent P/Q-type calcium channel subunit alpha-1A O00555 Details

References:

  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

13. Potassium voltage-gated channel subfamily H member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. Pubmed
  2. Cheng HC, Incardona J, McCullough B: Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):278-87. Epub 2006 Feb 28. Pubmed
  3. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. Pubmed
  4. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC: Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol. 2004 May;36(5):701-5. Pubmed
  5. Shimizu W, Aiba T, Antzelevitch C: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des. 2005;11(12):1561-72. Pubmed
  6. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

14. Sodium channel protein type 5 subunit alpha

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other

Components

Name UniProt ID Details
Sodium channel protein type 5 subunit alpha Q14524 Details

References:

  1. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10. Pubmed

15. ATP-sensitive inward rectifier potassium channel 11

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
ATP-sensitive inward rectifier potassium channel 11 Q14654 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Yamada S, Kane GC, Behfar A, Liu XK, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A: Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006 Dec 15;577(Pt 3):1053-65. Epub 2006 Oct 12. Pubmed
  3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. Pubmed

16. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed
  2. Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. Pubmed

2. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 2C18

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C18 P33260 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

9. Cytochrome P450 2B6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. Pubmed
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. Pubmed
  3. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. Pubmed
  4. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2®-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2®-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. Pubmed
  5. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. Pubmed
  6. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. Pubmed
  7. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. Pubmed
  8. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. Pubmed
  9. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. Pubmed
  10. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67. Pubmed
  11. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. Pubmed
  12. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. Pubmed
  13. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. Pubmed
  14. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. Pubmed
  15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. Pubmed
  16. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. Pubmed
  17. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. Pubmed
  18. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. Pubmed
  19. Pouliot JF, L’Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. Pubmed
  20. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. Pubmed
  21. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. Pubmed
  22. Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7. Pubmed
  23. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. Pubmed
  24. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. Pubmed
  25. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. Pubmed
  26. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3’,4’,5’-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9. Pubmed
  27. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. Pubmed
  28. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11. Pubmed
  29. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. Pubmed
  30. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. Pubmed
  31. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. Pubmed
  32. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. Pubmed
  33. Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63. Pubmed
  34. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. Pubmed
  35. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. Epub 2009 Nov 26. Pubmed
  36. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. Epub 2010 Jan 13. Pubmed
  37. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21. Pubmed
  38. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. Pubmed
  39. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. Epub 2009 Jun 18. Pubmed
  40. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12. Pubmed
  41. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25. Pubmed
  42. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. Pubmed
  43. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. Pubmed
  44. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. Pubmed
  45. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. Pubmed
  46. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. Pubmed
  47. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. Pubmed
  48. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. Pubmed
  49. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. Pubmed
  50. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. Pubmed

2. Solute carrier family 22 member 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 1 O15245 Details

References:

  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. Pubmed
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. Pubmed

3. Canalicular multispecific organic anion transporter 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 2 O15438 Details

References:

  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. Pubmed

4. Multidrug resistance-associated protein 4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 4 O15439 Details

References:

  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. Pubmed
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. Pubmed

5. Solute carrier family 22 member 5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 5 O76082 Details

References:

  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. Pubmed
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. Pubmed

6. Bile salt export pump

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Bile salt export pump O95342 Details

References:

  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. Pubmed

7. Multidrug resistance-associated protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 1 P33527 Details

References:

  1. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27. Pubmed

8. Solute carrier organic anion transporter family member 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. Pubmed
  2. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. Pubmed

9. Multidrug resistance-associated protein 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 7 Q5T3U5 Details

References:

  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. Pubmed

10. Canalicular multispecific organic anion transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. Pubmed

11. Solute carrier family 22 member 4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 4 Q9H015 Details

References:

  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. Pubmed
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. Pubmed

12. ATP-binding cassette sub-family G member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95. Pubmed

13. Solute carrier organic anion transporter family member 1B1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1B1 Q9Y6L6 Details

References:

  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. Epub 2009 Jan 12. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 15, 2016 17:38